Oncology · Medical Literature
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study.
Abstract
Here we report long-term outcomes of adjuvant metronomic capecitabine in patients with locoregionally advanced nasopharyngeal carcinoma. In this multicenter, open-label, parallel-group, randomized, controlled, phase 3 trial, 406 patients who had completed definitive chemoradiotherapy were randomly assigned (1:1) to receive either adjuvant metronomic capecitabine (650 mg m-2 twice daily for 1 year) or observation. The primary endpoint was failure-free survival; secondary endpoints included overall survival (OS), distant failure-free survival, locoregional failure-free survival, and safety, as reported in this analysis. The trial met its primary endpoint. With a median follow-up of 71.3 months, metronomic capecitabine significantly improved OS (hazard ratio = 0.53, 95% confidence interval, 0.31-0.91, P = 0.019). Grade 3 adverse events occurred in 35 (17%) of 201 patients in the metronomic capecitabine group and 11 (6%) of 200 in the observation group; one (<1%) grade 4 neutropenia was reported. In a post hoc analysis, completion of the 1 year course was associated with improved OS, whereas dose reductions and relative dose intensity showed no association with OS. Patients with a higher post-radiotherapy neutrophil-to-lymphocyte ratio derived greater benefit from metronomic capecitabine. These findings support the long-term therapeutic benefit of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma. ClinicalTrials.gov identifier: NCT02958111 .
Clinical relevance
In patients with high-risk locoregionally advanced nasopharyngeal carcinoma who have completed definitive chemoradiotherapy, does one year of adjuvant metronomic capecitabine (650 mg/m² twice daily) improve long-term failure-free survival and overall survival compared with observation alone? __SNAPSHOT__ {"studyDesign":"Multicenter, open-label, parallel-group, randomized, controlled, phase 3 trial (long-term follow-up report of NCT02958111)","setting":"14 hospitals in China; enrollment from January 25, 2017 to October 25, 2018","sampleSize":"n=406 (metronomic capecitabine: n=204; observation/standard therapy: n=202)","population":"Adults aged 18–65 years with histologically confirmed, high-risk locoregionally advanced NPC (stage III–IVA, excluding T3–4N0 and T3N1 disease), ECOG PS 0–1, no locoregional or distant metastasis after definitive chemoradiotherapy, and randomized 12–16 weeks after the final radiotherapy dose; approximately 78% had received induction chemotherapy","intervention":"Adjuvant metronomic capecitabine 650 mg/m² orally twice daily for 1 year","comparator":"Observation (standard therapy group)","primaryOutcome":"Failure-free survival (FFS), defined as time from randomization to disease recurrence [distant metastasis or locoregional recurrence] or death due to any cause, in the intention-to-treat population","followUp":"Median follow-up of 71.3 months (this long-term analysis); prior primary publication reported median follow-up of 38 months","fundingSource":"Government/non-profit: National Natural Science Foundation of China, Key-Area Research and Development Program of Guangdong Province, Natural Science Foundation of Guangdong Province, Innovation Team Development Plan of the Ministry of Education, and the Overseas Expertise Introduction Project for Discipline Innovation. No competing interests declared by authors."}
Key findings
The trial met its pre-specified primary endpoint of failure-free survival (reported previously; HR 0.50, 95% CI 0.32–0.79, p=0.0023 at 38-month median follow-up). In this long-term analysis at a median follow-up of 71.3 months, metronomic capecitabine significantly improved overall survival (OS) with HR=0.53 (95% CI 0.31–0.91, p=0.019). Absolute OS differences and median OS values were not reported in the available abstract. NNT for OS benefit is not calculable from the abstract alone. Grade 3 adverse events occurred in 35/201 (17%) patients in the capecitabine group versus 11/200 (6%) in the observation group (absolute risk difference: approximately 11% [calculated]). The most common grade 3 capecitabine-related adverse event was hand-foot syndrome (9% of capecitabine patients). One patient (<1%) in the capecitabine group developed grade 4 neutropenia; no grade 4 events were reported in the observation group, and no treatment-related deaths occurred in either group. In a post hoc analysis, completion of the full 1-year course was associated with improved OS, whereas dose reductions and relative dose intensity showed no statistically significant association with OS. A higher post-radiotherapy neutrophil-to-lymphocyte ratio (NLR) was identified as a potential predictive biomarker for greater benefit from metronomic capecitabine.
Practice implications
This long-term follow-up of a well-powered phase 3 RCT establishes that adjuvant metronomic capecitabine after definitive chemoradiotherapy confers a statistically significant and durable OS benefit (HR 0.53) in high-risk locoregionally advanced NPC at nearly 6 years of median follow-up, lending important credibility to findings initially demonstrated at 3 years. The trial does not establish efficacy in lower-risk NPC subgroups (T3–4N0, T3N1), in patients outside the 18–65 age range, or in populations outside endemic regions (virtually all data derived from China). The post hoc finding regarding course completion and the predictive role of NLR should be considered hypothesis-generating only and not used to guide clinical decisions without prospective validation. The open-label design precludes blinding, which is an inherent limitation for a maintenance oral agent trial but does not invalidate the OS endpoint. The absolute OS benefit magnitude cannot be precisely determined from the abstract alone, limiting full assessment of clinical magnitude. The ESMO–EURACAN guidelines already incorporate a grade IIB recommendation supporting adjuvant metronomic or standard-dose capecitabine in high-risk locoregionally advanced NPC. Only the abstract was available for this review; full-text data (absolute survival rates, Kaplan–Meier curves, subgroup analyses, and secondary endpoint details) should be consulted before applying findings in complex cases. __LIMITATIONS__ Open-label design introduces potential for performance and detection bias, though OS as an endpoint mitigates ascertainment bias.,Single-country (China) trial population limits direct generalizability to non-endemic, Western NPC populations with different EBV epidemiology, histology distribution, and treatment practices.,Absolute OS rates and median OS values are not reported in the abstract; clinical magnitude of OS benefit cannot be fully assessed without full-text data.,The post hoc nature of the course-completion and NLR analyses introduces substantial risk of confounding and multiple testing; these findings should not drive clinical decisions without prospective validation.,Approximately 78% of patients received induction chemotherapy, which may limit generalizability to settings where induction chemotherapy is not routine.,Specific NNT for OS and FFS cannot be calculated without Kaplan–Meier survival estimates at defined time points.,Long-term toxicity data (late effects of capecitabine), quality-of-life outcomes at extended follow-up, and secondary malignancy rates are not reported in the abstract.,Stage exclusions (T3–4N0 and T3N1) mean lower-risk disease subgroups remain unstudied by this trial.,The original trial was powered for FFS, not OS; although the OS result is statistically significant, it may reflect a secondary analysis not adequately powered for that endpoint. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ This long-term phase 3 RCT demonstrates that one year of adjuvant metronomic capecitabine (650 mg/m² BID) after definitive chemoradiotherapy significantly improves overall survival (HR 0.53, 95% CI 0.31–0.91, p=0.019) at a median follow-up of nearly 6 years in high-risk locoregionally advanced NPC, with a manageable toxicity profile dominated by grade 3 hand-foot syndrome (9%) and no treatment-related deaths. These durable OS data, in the context of existing guideline support (ESMO–EURACAN IIB), strengthen the case for routine adoption of this regimen in eligible patients (stage III–IVA, excluding T3–4N0 and T3N1) who have achieved remission after chemoradiotherapy. Clinicians practicing outside China should exercise judgment regarding generalizability given the exclusively Chinese study population, and should obtain and review full-text data before applying the post hoc biomarker findings.